Apr 06, 2026 | Gilead's $3.15B Tubulis ADC Deal; Neurocrine's $2.9B Prader-Willi Bet

Gilead pays $3.15B for ADC specialist Tubulis — third dealin six weeks. Neurocrine bets $2.9B on Soleno for Prader-Willi, Merck reprices Terns by $1B after data peek, and Sanofi's bispecific lunsekimig hits in asthma but misses in eczema. Plus Novo launches high-dose Wegovy.www.thepharmacloseout.compharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, Gilead, Tubulis, ADC, antibody-drug conjugate, Neurocrine, Soleno, Prader-Willi, Vykat, Merck, Terns Pharmaceuticals, TERN-701, CML, Sanofi, lunsekimig, Amgen, Tepezza,teprotumumab, Novo Nordisk, Wegovy, semaglutide, AbbVie, Humira, TrumpRx, ImmunityBio, Anktiva, M&A, oncology, rare disease, Pfizer, Lilly, AstraZeneca